E-mail: Hana.Klamova@uhkt.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- HIGH SENSITIVITY MUTATION SCREENING AND CLONAL ANALYSIS ALLOWED BY ULTRA-DEEP AMPLICON SEQUENCING UNCOVER THE COMPLEXITY OF BCR-ABL MUTATION STATUS IN PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS
- ABNORMALITY OF GLUCOSE AND LIPID METABOLISM DURING NILOTINIB THERAPY – RESULTS OF ENIGMA 2 STUDY
- Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia
- ALLOGENEIC TRANSPLANTATION IN ADVANCED STAGES OF CML IN THE THIRD MILLENIUM. IS THERE A DIFFERENCE ?
- BCR-ABL MUTATED CLONE PROGRESSION AND ELIMINATION IN CML PATIENTS TREATED WITH ABL KINASE INHIBITORS
- Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study
- COMPLETE CYTOGENETIC RESPONSE AFTER 12 MONTHS OF TREATMENT AND WITHIN 1 YEAR OF IMATINIB THERAPY IN PATIENTS WITH LATE CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PH+
- DASATINIB - LÉČBA NEMOCNÝCH S CML REZISTENTNÍCH NA IMATINIB A PRVNÍ ZKUŠENOSTI Z REÁLNÉ KLINICKÉ PRAXE V ČR
- DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
- DASATINIB EVEN AT LOWER DOSES IS AN EFFECTIVE FOR CHRONIC MYELOID LEUKAEMIA TREATMENT IN PATIENTS RESISTANT OR INTOLERANT TO IMATINIB
- DEEP SEQUENCING OF THE BCR-ABL KINASE DOMAIN REVEALS A FREQUENCY OF 35INS INSERTION/TRUNCATION HIGHER THAN EXPECTED
- DIFFERENT CONTROL GENES IN BCR/ABL MONITORING BY REAL-TIME RT-PCR
- Differential Expression of miRNAs during the Course of Chronic Myeloid Leukemia
- Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications
- DNA Based Detection and Quantification of BCR-ABL1 Gene Using Patient-Specific qPCR and Droplet Digital PCR Tests in Chronic Myeloid Leukemia
- EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE
- ESTIMATION OF THE CURRENT SURVIVAL MEASURES IN CHRONIC MYELOID LEUKEMIA: METHODOLOGY AND NEW SOFTWARE TOOLS
- Expression Analysis of WT1 Splicing Variants In CML and AML: –5/+KTS as a Novel Candidate for Early Marker of Relapse
- EXPRESSION LEVELS OF MIR-150 AND TRANSCRIPTION FACTORS PU.1, EGR2 INVERSELY CORRELATE WITH MYB AND MYCN IN CHRONIC MYELOID LEUKEMIA
- Expression of Four Major WT1 Splicing Variants in AML and CML: Development of Quantitative Real-Time PCRs and Preliminary Results in Patient Samples
- GENOMIC BCR-ABL1 FUSION CHARACTERISATION AND SNPS IDENTIFICATION UPSTREAM AND DOWNSTREAM OF THE BREAKPOINTS IN BCR AND ABL1 GENES OF CML PATIENTS USING NEXT GENERATION SEQUENCING
- HAS SIMULTANEOUS PREGNANCY NEGATIVELY INFLUENCED PROGRESSION AND TREATMENT RESPONSE IN CML?
- HSP 90 AS A POSSIBLE INDICATOR OF DISEASE DETERIORATION IN CHRONIC MYELOID LEUKEMIA
- IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. CAN WE COMPARE THE REAL-LIFE DATA TO CLINICAL TRIAL RESULTS?
- IMATINIB IN THE FIRST-LINE CML TREATMENT: AN ANALYSIS OF A COMPREHENSIVE NON-COMMERCIAL DATABASE OF ALL CONSECUTIVE PATIENTS IN A DEFINED POPULATION
- IMATINIB IN THE TREATMENT OF ELDERLY PATIENTS WITH PH CML IN THE LATE CHRONIC PHASE
- In Vitro Sensitivity to Tyrosine Kinase Inhibitors Is One of Possible Predictive Parameters for Therapy Switch In Patients with Chronic Myeloid Leukemia
- INTERFERON-ΑLPHA REVISITED: INDIVIDUALIZED IMMUNE-MODULATION EASED UP SELECTION PRESSURE OF TKI ON BCR-ABL MUTATED CLONES AND IMPROVES MOLECULAR RESPONSE IN HIGH-RISK CML PATIENTS
- IS THE HIGH-THROUGHPUT DROPLET DIGITAL PCR A NEXT-GENERATION TECHNOLOGY FOR ACCURATE AND SENSITIVE BCR-ABL1 QUANTIFICATION FOR DEEP MOLECULAR RESPONSE MONITORING IN CML?
- Kdy a jak analyzovat mutace v kinázové doméně BCR-ABL u pacientů s CML?
- Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders
- Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain
- MIR-451 MAY POSITIVELY REGULATE MDR1 IN CHRONIC MYELOID LEUKEMIA
- MONITORING OF TOTAL WT1 EXPRESSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML): WT1 AS A HELPFUL MARKER BESIDES BCR-ABL
- Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment
- PHOSPHO TYROSINE KINASE PROFILLING IN PRIMARY CULTURES FROM PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- PHOSPHOPROTEOM ANALYSIS OF CHRONIC MYELOID LEUKEMIA CELLS USING PROTEIN ARRAYS
- PREDICTION OF IMATINIB THERAPY RESPONSE: A ROLE OF INTRACELLULAR TRANSPORTERS HOCT-1 AND ABCB1
- PROGNOSTIC SIGNIFICANCE OF COMPLEX CHROMOSOMAL REARRANGEMENTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- RESISTANCE TO IMATINIB: WT-1 AS A POSSIBLE MARKER FOR THE EVALUATION OF UPFRONT RESISTANCE, ROLE OF KINASES OTHER THAN BCR-ABL IN SECONDARY RESISTANCE
- RESPONSE OF SECONDARY CHRONIC MYELOID LEUKEMIA TO IMATINIB. COOPERATIVE STUDY OF CML REGISTRIES CAMELIA AND INFINITY
- SHORT WT1 VARIANT OF WILMS TUMOR GENE IS EXPRESSED IN LEUKEMIC CELL LINES, PATIENTS WITH AML, MDS AND IN CML BLAST CRISIS
- SNPs in the Promoter of the Gene Encoding Transmembrane Transporter SLC22A4 (hOCTN1) Are Significantly Associated with an Alteration of Gene Expression and with Resistance to the Imatinib Treatment in Chronic Myeloid Leukemia
- SUCCESSFUL MANAGEMENT OF CML DURING PREGNANCY AND IN POST-PARTUM PERIOD
- The Gene Expressions of hOCT1 and ABCB1 Change During the Course of CML in Relation to Imatinib Therapy
- THE IMPACT OF THERAPY INTENSIFICATION AND OUTCOME OF 6 CML PATIENTS WITH THE SAME TYPE OF BCR-ABL MUTATION M244V
- The Musashi 2 mRNA Expression in the Course of CML
- The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–20
- The Plateau of BCR-ABL Transcript Level =;>0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.
- To the computer assisted heterochromation densitometry of lymphocytes
- Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy
- ULTRA-DEEP SEQUENCING WITH COMPUTED THRESHOLDS FOR SENSITIVE MUTATION ANALYSIS IN THE KINASE DOMAIN OF BCR-ABL: FOCUSED ON DEEP MUTATION DETECTION IN CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE
- Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation
